PCOS Has Been Renamed PMOS — Here's What It Means for Your Fertility | Mitra Fertility & Beyond

If you have PCOS — or think you might — there is news you need to know about. Yesterday, 12 May 2026, one of the most widely-used diagnoses in women's health was officially renamed. In a landmark paper published in The Lancet, leading clinicians and patient organisations from around the world announced that Polycystic Ovary Syndrome (PCOS) will now be called Polyendocrine Metabolic Ovarian Syndrome — PMOS.

One letter changed. But the reasons behind it matter enormously — especially for women who are trying to conceive.

This article explains what changed, why it changed, and most importantly, what it means for you if you're on a fertility journey.

Why was PCOS renamed?

The name "Polycystic Ovary Syndrome" has frustrated doctors and patients for decades — and for good reason. It describes the condition by one feature visible on ultrasound: the appearance of multiple small follicles on the ovaries that resemble cysts.

The problem is that this name is misleading in almost every direction.

The "cysts" aren't actually cysts. They are immature follicles — eggs that started developing but didn't complete the process. A true cyst is a fluid-filled sac. These are nothing of the sort.

Not every woman with PCOS has polycystic ovaries. You can be diagnosed with PCOS without polycystic ovary morphology on your scan. The diagnosis depends on a combination of three criteria — irregular ovulation, elevated androgens (male hormones), and polycystic ovary appearance — and you only need two of the three. Millions of women with this condition have been confused, and sometimes dismissed, because their ovaries "didn't look polycystic."

The name completely hides what the condition actually is. PCOS is not primarily a problem with cysts. It is a hormonal and metabolic condition — one that affects your insulin sensitivity, your androgen levels, your menstrual cycle, your weight, your skin, your mental health, and yes, your fertility. Calling it a syndrome about ovarian cysts is like calling type 2 diabetes "sweet urine syndrome." Technically observable, fundamentally misleading.

The name change was published in The Lancet on 12 May 2026, with authors noting that PCOS as a term was "inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing."

This was not a decision made lightly or quickly. After hearing from 22,000 people over 11 years, the condition was renamed following a rigorous global scientific process. The name change came as a result of collaboration across 56 leading academic, clinical, and patient organisations, as well as iterative global surveys that garnered responses from over 14,300 people with PCOS and multidisciplinary health professionals from all world regions.

What does PMOS stand for — and what does the new name tell us?

P — Polyendocrine: This acknowledges that the condition involves multiple hormonal systems, not just one. It's not just androgens. It involves insulin, LH, FSH, oestrogen, and often thyroid and adrenal hormones too. The "poly" here is accurate — this is a multi-gland, multi-hormone condition.

M — Metabolic: This is perhaps the most important addition. PMOS is fundamentally a metabolic condition. Insulin resistance is at its core in the majority of cases. That connection — between insulin, androgens, ovulation, and fertility — is central to understanding both the condition and how to treat it. Naming it explicitly as metabolic changes how doctors think about it, how it's taught, and potentially how it's classified in insurance and research funding.

O — Ovarian: The ovaries remain central to the condition's reproductive effects. The name doesn't abandon this — it just puts it in its proper context.

S — Syndrome: A syndrome is a collection of features that tend to occur together. That remains accurate. PMOS presents differently in different women — some have all features, some have a few, some have symptoms that fluctuate over time.

PMOS is characterised by fluctuations in hormones, with impacts on weight, metabolic and mental health, skin, and the reproductive system. The new name captures all of this. The old one captured only the last.

What does this mean for women trying to conceive?

The name has changed. The condition has not. If you were diagnosed with PCOS last year, you still have the same condition — it is now called PMOS. Your diagnosis is valid. Your treatment plan is not affected. Your fertility outlook has not changed.

But the name change carries real implications for the future of fertility care for women with PMOS, and I want to be honest about what those are.

 

1. Faster diagnosis, less confusion

One of the most consistent harms of the PCOS label has been diagnostic delay. Women with irregular periods and elevated androgens but no polycystic ovaries on scan were often told they didn't have PCOS — even when all other features were present. Women without obvious "cysts" spent years in diagnostic limbo.

The new name removes the cyst requirement from the conceptual centre of the condition. A doctor who understands PMOS as a hormonal-metabolic syndrome is less likely to dismiss a patient whose ultrasound doesn't match the old mental image. Earlier diagnosis means earlier treatment — and in fertility, earlier treatment matters a great deal.

2. Insulin resistance will be taken more seriously

Under the old framing, insulin resistance was a "feature" of PCOS — an associated finding, something to manage alongside the main problem. Under the PMOS framing, metabolic dysfunction is named in the condition itself. This is likely to shift clinical practice toward screening for and treating insulin resistance more proactively — which directly benefits fertility.

Insulin resistance suppresses ovulation. Managing it — through diet, exercise, and where appropriate, metformin — is one of the most effective things a woman with PMOS can do to improve her chances of conceiving, whether naturally or with treatment. If PMOS gets more metabolic attention as a result of the name change, women trying to conceive will benefit.

3. The emotional weight of the diagnosis may shift

This matters more than it might seem. The word "polycystic" has caused enormous distress. Women pictured their ovaries covered in cysts. They were told they had a "cystic condition." The language implied something broken, something blocked, something structurally wrong.

PMOS doesn't carry that imagery. It's more accurate, and in being more accurate, it may be less frightening. A woman who understands she has a hormonal and metabolic condition — one that is manageable, one that responds to lifestyle and medical treatment — is better placed to engage with her care than one who believes her ovaries are covered in cysts.

"Language matters in medicine," said one of the researchers involved in the process. "The previous name often led to misconceptions and stigma, particularly around fertility."

4. Better research, better treatments in future

Research funding, drug trials, and clinical guidelines are all shaped by how a condition is classified and named. A condition framed as primarily hormonal-metabolic will attract different research attention than one framed as an ovarian structural problem. Over time, this should lead to better-targeted treatments — particularly for the metabolic and insulin components that drive so much of the fertility challenge in PMOS.

What hasn't changed

Everything we know about treating PMOS-related infertility remains the same. The name is new. The science is not.

Letrozole remains the first-line medication for ovulation induction. It works by stimulating follicle development and is more effective than clomiphene in PMOS.

Metformin remains a valuable support, particularly for women with confirmed insulin resistance, and is most effective in combination with letrozole.

IUI (Intrauterine Insemination) remains the recommended second-line treatment when ovulation induction with timed intercourse hasn't resulted in pregnancy.

IVF remains highly effective for PMOS — and women with PMOS tend to produce a good number of eggs in response to stimulation. The key precaution — the risk of Ovarian Hyperstimulation Syndrome (OHSS) — also remains unchanged, and should always be discussed with your doctor.

Lifestyle remains important. For women who are overweight, a 5–10% reduction in body weight can restore spontaneous ovulation in some cases and significantly improves response to medication. Diet choices that support insulin sensitivity — lower refined carbohydrates, higher protein and fibre — continue to support treatment.

None of this has changed. What may change over time is how thoroughly these approaches are applied, how quickly women are diagnosed, and how seriously the metabolic dimension of the condition is addressed alongside the reproductive one.

A note on what to call it going forward

In India, PCOS is an extremely well-known term. Your family members know it. Your GP knows it. It will be in use for some time — in clinical notes, in conversations, on prescription pads. The transition to PMOS will not happen overnight, and there is no need to be confused or alarmed if your doctor continues using PCOS for now.

At Mitra Fertility, we will be using PMOS in our communications going forward — because the name is better, because it reflects the science, and because our patients deserve language that accurately describes what they're dealing with. If you have a diagnosis of PCOS, that diagnosis is now PMOS. Nothing about your condition or your care has changed — the name has simply become more honest.

What to do if you have PMOS and want to conceive

The name change doesn't change the urgency, the approach, or the options.

If you have PMOS and you're trying to conceive — or planning to in the next few years — the most useful thing you can do is get a proper fertility assessment. That means:

• Hormone blood tests: AMH, FSH, LH, testosterone, insulin, thyroid
• An antral follicle count scan to assess your ovarian reserve
• A semen analysis for your partner
• A clear conversation with a fertility specialist about what your results mean and what the realistic options are for your situation

PMOS is treatable. Most women with PMOS who want to become pregnant, do. The key is starting with the right information and the right support — not waiting, and not being misled by either excessive pessimism or unrealistic promises.

If you'd like to discuss what PMOS means for your fertility specifically, we offer consultations at Mitra Fertility & Beyond — including free OPD every Sunday by appointment. We're here to give you honest answers, not a package.

Frequently asked questions

1.      I was diagnosed with PCOS. Do I need a new diagnosis? No. Your existing diagnosis is valid. PCOS and PMOS refer to the same condition — PMOS is simply the new, more accurate name. You don't need any new tests or paperwork.

2.      Has anything about the diagnostic criteria changed? The criteria themselves — irregular ovulation, elevated androgens, and polycystic ovary morphology on scan (two out of three required) — have not changed with the renaming. Updates to clinical guidelines are expected to follow the name change over the coming months, and may refine some aspects of diagnosis and management.

3.      Will my medication change? No. Letrozole, metformin, and other treatments for PMOS remain the same. The name change does not affect any current treatment protocols.

4.      Why haven't I heard about this in India yet? The paper was published in The Lancet on 12 May 2026 — yesterday. This is genuinely new. It will take time for the name to filter into clinical practice across India. But the science behind the change has been building for over a decade.

5.      Does PMOS mean I'm less likely to conceive than someone with PCOS? You have the same condition under a different name. Your fertility outlook is exactly the same as it was before the name changed.

6.      Is PMOS harder to treat than PCOS was? No. Again — same condition, same treatments. If anything, the more accurate framing of PMOS as a metabolic-hormonal syndrome may lead to better treatment over time, as the insulin component receives more clinical attention.

---

Dr Vidyalatha Atluri is the Founder & Managing Director of Mitra Fertility & Beyond, Hyderabad. She specialises in reproductive medicine and the management of PMOS (previously PCOS), endometriosis, low AMH, and recurrent pregnancy loss.

To book a consultation, contact Mitra Fertility & Beyond on WhatsApp or call the clinic directly. Free OPD consultations with Dr Vidya are available every Sunday — by appointment.

---

© 2026 Mitra Fertility & Beyond. This article is for informational purposes and does not constitute medical advice. Please consult a qualified fertility specialist for guidance specific to your situation. Source: Teede et al., "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." The Lancet, 12 May 2026.